Insulet Corporation (PODD) Stock Analysis — Fair Value, Risk & Moat Rating
NMS · Healthcare · Medical Devices
Is Insulet Corporation a safe investment right now?
Insulet Corporation's Altman Z-Score of 1.85 places it in the gray zone. Our fair value estimate is $140.00 (Overvalued). Moat rating: 3.7/5 stars.
Could Insulet Corporation go bankrupt? Altman Z-Score analysis
Z-Score of 1.85 places the company in the gray zone (1.8-3.0), warranting closer scrutiny.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives PODD's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.3868 | 1.2 | 0.46 |
| B · Retained Earnings / Total Assets | RE / TA | 0.0901 | 1.4 | 0.13 |
| C · EBIT / Total Assets | EBIT / TA | 0.125 | 3.3 | 0.41 |
| D · Market Cap / Total Liabilities | MCap / TL | 0 | 0.6 | 0.0 |
| E · Revenue / Total Assets | Rev / TA | 0.8488 | 1.0 | 0.85 |
How has PODD's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 5.4 | Safe |
| 2023 | 5.7 | Safe |
| 2024 | 5.94 | Safe |
| 2025 | 1.85 | Gray |
Source: Calculated from PODD's latest 10-K filing on SEC EDGAR.
What is Insulet Corporation actually worth?
How we calculated this
| Input | Value | Source |
|---|---|---|
| Predicted EPS (α) | $3.50 | Proprietary blend of reported actuals (4Q actual) + analyst consensus, weighted by α |
| Last Year EPS | $5.78 | Annual report (SEC EDGAR) |
| Analyst Consensus EPS (This Year) | $6.34 | 23 analysts consensus |
| Trailing P/E | 55.5x | Current market pricing |
| Fair P/E (β discount) | 40.0x | Trailing PE adjusted by value discount factor β, hard-capped |
| Earnings Trend (γ) | Stable | Directional signal: predicted vs trailing EPS |
Wall Street Reference: Analyst consensus target price is $333.30 (23 analysts). This is shown for reference only and is not used in our valuation model.
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does Insulet Corporation have a durable competitive advantage?
Moat rating: 3.7/5.
What makes up PODD's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 4/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 4/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is PODD's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | 2.4% | — |
| 2023 | 11.7% | Rising |
| 2024 | 13.2% | Rising |
| 2025 | 16.2% | Rising |
Source: ROIC calculated from SEC EDGAR filings.
Is Insulet Corporation's dividend safe?
Insulet Corporation's key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $2.7B | $2.1B | $1.3B | Rising |
| Net Income | $0.2B | $0.4B | $0.0B | Rising |
| Free Cash Flow | $0.3B | $0.3B | −$0.0B | Rising |
| Gross Margin | 71.6% | 69.8% | 61.7% | Rising |
Recent events that affect our PODD analysis
PODD earnings report scheduled
Upcoming report. Consensus EPS estimate: $1.19. Revenue estimate: $730.1M. Our current Fair Value: $140.00 — a significant beat or miss could shift this estimate.
PODD analyst consensus: 88% bullish (21 of 24 analysts)
5 Strong Buy, 16 Buy, 2 Hold, 0 Sell, 1 Strong Sell. Consensus target: $333.30 (72.1% upside). Compare with our independent Fair Value: $140.00.
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD beat EPS estimates by 6.0%
Reported EPS: $1.55 vs estimate $1.46. Earnings strength supports our Fair Value of $140.00 (27.7% below current price).
PODD filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD beat EPS estimates by 8.1%
Reported EPS: $1.24 vs estimate $1.15. Earnings strength supports our Fair Value of $140.00 (27.7% below current price).
PODD filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD beat EPS estimates by 26.8%
Reported EPS: $1.17 vs estimate $0.92. Earnings strength supports our Fair Value of $140.00 (27.7% below current price).
PODD filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
PODD beat EPS estimates by 29.7%
Reported EPS: $1.02 vs estimate $0.79. Earnings strength supports our Fair Value of $140.00 (27.7% below current price).
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PODD filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
PODD beat EPS estimates by 12.6%
Reported EPS: $1.15 vs estimate $1.02. Earnings strength supports our Fair Value of $140.00 (27.7% below current price).
PODD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
Common questions about Insulet Corporation
What is Insulet Corporation stock price today?
Insulet Corporation (PODD) stock price is $193.62 as of the latest market close, traded on the NASDAQ exchange.
What does Insulet Corporation do?
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. It offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.
What is Insulet Corporation market cap?
Insulet Corporation has a market capitalization of $13.63B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is PODD in?
Insulet Corporation operates in the Healthcare sector, specifically within the Medical Devices industry. It trades on the NASDAQ under the ticker symbol PODD.
Is PODD stock overvalued or undervalued?
Based on our valuation model, Insulet Corporation trades 38.3% above our fair value estimate — potentially overvalued.
- FairValueLabs Fair Value: $140.00
- Current Price: $193.62
- Valuation Zone: Overvalued
What is PODD stock forecast and analyst target price?
Based on 23 Wall Street analysts, the consensus price target for Insulet Corporation is $333.30, implying upside of 72.1% from the current price.
- Analyst High Target: $435.00
- Analyst Low Target: $230.00
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is Insulet Corporation revenue and earnings growing?
Here are the analyst consensus growth estimates for Insulet Corporation:
- Revenue growth (current year est.): 22.0%
- EPS growth (current year est.): 27.7%
- Revenue growth (next year est.): 19.2%
- EPS growth (next year est.): 27.4%
What are Insulet Corporation's key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $2.7B | Rising |
| Net Income | $0.2B | Rising |
| Free Cash Flow | $0.3B | Rising |
| Gross Margin | 71.6% | Rising |
What is PODD's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Trailing P/E (last 12 months): 55.5x
- Forward P/E (next 12 months est.): 24.0x
- FairValueLabs Fair P/E: 40.0x
How volatile is PODD stock?
Insulet Corporation has a beta of 1.47, meaning it is somewhat more volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does Insulet Corporation have?
Insulet Corporation's balance sheet shows:
- Total Cash: $716.1M
- Total Debt: $1.00B
- Net Cash Position: $-286.6M
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is Insulet Corporation's free cash flow?
Insulet Corporation generated $154.9M in trailing twelve-month free cash flow (from $569.3M in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does Insulet Corporation pay a dividend?
Insulet Corporation does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.
Is Insulet Corporation at risk of going bankrupt?
Insulet Corporation's Altman Z-Score is 1.85, placing it in the gray zone (1.8–3.0) — some financial uncertainty. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does Insulet Corporation have a durable competitive advantage?
Insulet Corporation scores 3.7/5 stars (Solid moat · eroding) in our moat analysis:
- ROIC Stability: 4/5
- Gross Margin Trend: 4/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is PODD's return on equity (ROE)?
Insulet Corporation's return on equity is 18.1%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy PODD stock?
PODD shares can be purchased through any brokerage account that provides access to the NASDAQ. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol PODD
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is PODD a value stock or speculative?
FairValueLabs classifies Insulet Corporation as Value-Speculation. It has some value characteristics but carries elevated risk factors that make it speculative. Extra due diligence is recommended.
Who is the CEO of Insulet Corporation?
The current CEO of Insulet Corporation is Ms. Ashley A. McEvoy.
What is PODD's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $3.49
- Forward EPS (next 12 months est.): $8.08
- Analyst consensus EPS (this year): $6.34
- Analyst consensus EPS (next year): $8.08
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
PODD analysis methodology: How we calculate fair value, Z-Scores, and moat ratings